Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIYAIRI-BM + magnesium oxide
- Development stage
- Phase 4
- Lead developer
- Miyarisan Pharmaceutical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
MIYAIRI-BM + magnesium oxide is a combination therapy being evaluated for the treatment of functional constipation, particularly in pediatric populations. MIYAIRI-BM is a probiotic preparation containing *Clostridium butyricum* MIYAIRI 588, a spore-forming, gram-positive anaerobe that produces butyric acid. Butyrate serves as a primary energy source for colonocytes and helps regulate intestinal motility and inflammation. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen, softening stools and increasing bowel movement frequency. This combination aims to address both the physiological symptoms of constipation and the underlying dysbiosis of the intestinal microflora.
- Other names
- Clostridium butyricum MIYAIRI 588 + magnesium oxideCBM 588 + MgO
Beyond the preview
Go deeper on MIYAIRI-BM + magnesium oxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIYAIRI-BM + magnesium oxide.